Anti-EIF2AK2, NT (Eukaryotic Translation Initiation Factor 2-alpha Kinase 2, eIF-2A Protein Kinase 2

Anti-EIF2AK2, NT (Eukaryotic Translation Initiation Factor 2-alpha Kinase 2, eIF-2A Protein Kinase 2
Artikelnummer Größe Datenblatt Manual SDB Lieferzeit Menge Preis
E8949-16-HRP.200 200 µl - -

3 - 19 Werktage*

790,00 €
 
Interferon-induced, double-stranded RNA-activated protein kinase (PRKR) is a serine-threonine... mehr
Produktinformationen "Anti-EIF2AK2, NT (Eukaryotic Translation Initiation Factor 2-alpha Kinase 2, eIF-2A Protein Kinase 2"
Interferon-induced, double-stranded RNA-activated protein kinase (PRKR) is a serine-threonine kinase. Activation by dsRNAs leads to autophosphorylation of PRKR and allows the kinase to phosphorylate its natural substrate, the alpha subunit of eukaryotic protein synthesis initiation factor-2 (EIF2-alpha), leading to the inhibition of protein synthesis. Human gamma-interferon (IFNG) mRNA exploits localized activation of PRKR in the cell to regulate its own translation. IFNG mRNA activates PRKR through a pseudoknot in its 5-prime untranslated region. The HCV envelope protein E2 contains a sequence identical with phosphorylation sites of the interferon-inducible protein kinase PRKR and the translation initiation factor EIF2-alpha, a target of PRKR. E2 inhibits the kinase activity of PRKR and blocks its inhibitory effect on protein synthesis and cell growth, which provides one mechanism by which HCV may circumvent the antiviral effect of interferon. PRKR, which is involved in TLR signaling and mediates apoptosis in fibroblasts in response to viral infection and inflammatory cytokines, also activates IKK and NFKB, thereby suppressing apoptosis. Apoptosis induced by live pathogenic gram-positive and gram-negative bacteria requirs both TLR4 and PRKR, possibly representing a major mechanism for pathogenic bacteria that use specific virulence factors to avoid detection and destruction by the innate immune system. Roles for PRKR activation in Huntington disease and Fanconi anemia have also been suggested. Applications: Suitable for use in ELISA, Western Blot, and Immunohistochemistry. Other applications not tested. Recommended Dilution: ELISA: 1:1,000, Western Blot: 1:100-1:500, Immunohistochemistry: 1:50-1:100, Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap., , Note: Applications are based on unconjugated antibody.
Schlagworte: Anti-PKR, Anti-EIF2AK2, Anti-p68 kinase, EC=2.7.11.1, EC=2.7.10.2, Anti-Protein kinase R, Anti-eIF-2A protein kinase 2, Anti-P1/eIF-2A protein kinase, Anti-Protein kinase RNA-activated, Anti-Tyrosine-protein kinase EIF2AK2
Hersteller: United States Biological
Hersteller-Nr: E8949-16-HRP

Eigenschaften

Anwendung: ELISA, IHC, WB
Antikörper-Typ: Polyclonal
Konjugat: HRP
Wirt: Rabbit
Reaktivität: Human, Mouse
Immunogen: Synthetic peptide selected from the N-terminal region of human PRKR (KLH).
Format: Purified

Handhabung & Sicherheit

Lagerung: -20°C
Versand: +4°C (International: +4°C)
Achtung
Nur für Forschungszwecke und Laboruntersuchungen: Nicht für die Anwendung im oder am Menschen!
Hier folgen Informationen zur Produktreferenz. mehr
Hier kriegen Sie ein Zertifikat
oder , um Analysenzertifikate anzufordern.
Bewertungen lesen, schreiben und diskutieren... mehr
Kundenbewertungen für "Anti-EIF2AK2, NT (Eukaryotic Translation Initiation Factor 2-alpha Kinase 2, eIF-2A Protein Kinase 2"
Bewertung schreiben
oder , um eine Produktbewertung abzugeben.
Zuletzt angesehen